tiotropium-bromide and Bronchiectasis

Bronchiectasis, a common chronic respiratory disease, is characterized by irreversible and abnormal bronchial dilatation due to multiple causes. In 2021, a series of significant research progress have been made in bronchiectasis, focusing on the mechanism, diagnosis, clinical phenotypes, treatment, comorbidities,. 支气管扩张症（简称支扩）是一种常见的慢性气道疾病，由各种原因导致的支气管不可逆及异常扩张。2021年支扩研究领域取得一系列重要进展，聚焦于机制研究、诊断、分型、治疗及合并症等。研究发现脂质、血小板、呼吸道微生物与支扩病情密切相关，为开发支扩的防治靶点提供了新见解。国际专家共识定义了纳入临床试验中支扩患者的影像学和临床诊断标准。新支扩表型的提出、评估工具的推广及预测因素的发现，推进了支扩个体化治疗的进程。支扩治疗相关的临床研究已发表，如吸入妥布霉素粉剂、气道廓清技术、噻托溴铵等。此外，支扩肺部合并症相关的研究亦有新发现。本文对最新发表的文献进行了归纳分析，以期对临床医生认识支扩有所裨益。.

Topics: Bronchi; Bronchiectasis; Consensus; Humans; Tiotropium Bromide

Topics: Bronchiectasis; Bronchodilator Agents; Humans; Tiotropium Bromide

Tiotropium. In a randomised, double-blind, two-period crossover trial, we recruited adult patients from three hospitals in New Zealand. Patients were excluded if they had a smoking history of >20 pack-years. Patients were assigned to either the tiotropium-placebo or placebo-tiotropium sequence in a 1:1 ratio, using randomly permuted blocks stratified by centre. Participants and investigators were masked to treatment allocation. Eligible patients received tiotropium 18 μg. 90 patients were randomly assigned and 85 completed both treatment cycles. The rate of exacerbations was 2.17 per year under the tiotropium treatment and 2.27 per year under placebo (rate ratio 0.96, 95% CI 0.72-1.27; p=0.77). Tiotropium, compared with placebo, improved forced expiratory volume in 1 s by 58 mL (95% CI 23-92 mL; p=0.002). Adverse events were similar under both treatments.

Topics: Adult; Bronchiectasis; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Forced Expiratory Volume; Humans; Pulmonary Disease, Chronic Obstructive; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome

To observe the therapeutic effect of tiotropium bromide powder inhalation on stable bronchiectasis.. Twenty-two patients with stable bronchiectasis received inhalation of totropium bromide powder at the daily dose of 18 microg, and on days 1 and 28, the patients were examined for forced expiratory volume in one second (FEVl), predicted value [FEVl(%)], forced expiratory volume (FEV), and FEVl/FVC. The symptom score and BODE index were also recorded.. After 1 month of inhalation therapy, the FEV1% of the patients showed a moderate increase but the increment was not statistically significant (t=-1.875, P>0.05); the symptom score and BODE index decreased significantly after the therapy (t=7.091, P<0.001; t=2.982, P<0.05).. Long-term inhalation of tiotropium bromide powder can improve the clinical symptoms and BODE index and enhance the exercise tolerance and quality of life of the patients with bronchiectasis.

Topics: Administration, Inhalation; Adult; Aged; Bronchiectasis; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Powders; Receptor, Muscarinic M3; Scopolamine Derivatives; Tiotropium Bromide

There are limited studies on the use of bronchodilators for the treatment of bronchiectasis. This study investigated the efficacy of tiotropium in patients with bronchiectasis and airflow limitation.. This study was a prospective cohort study, including 169 patients with bronchiectasis and airflow limitation from 2015 to 2019. The clinical outcomes observed in our study were the effect of tiotropium on the frequency of moderate exacerbations, the time to the first severe exacerbation, and the annual decline in FEV. After 12 months, the annual decline in the FEV. In conclusion, prospective cohort study showed that tiotropium effectively ameliorated the annual decline in the FEV

Topics: Bronchiectasis; Bronchodilator Agents; Humans; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome

Topics: Administration, Inhalation; Bronchiectasis; Bronchodilator Agents; Humans; Pulmonary Disease, Chronic Obstructive; Tiotropium Bromide

Topics: Bronchiectasis; Bronchodilator Agents; Cross-Over Studies; Humans; Tiotropium Bromide